104 completed, 25 terminated, 16 unknown, 7 withdrawn. 49 Phase 2, 36 Phase 3, 28 Phase 1, 25 Phase 4, 21 Not applicable.
Follow Octreotide: new trials by email Literature Review of Octreotide trials Research Report on Octreotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia | Phase 1 | Not yet recruiting | Columbia University | 36 | 2027-01-01 | 2026-02-06 |
| Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema Octreotide (drug), Placebo - Diabetic Macular Edema | Phase 1 | Withdrawn | University of Alabama at Birmingham | 2026-08-31 | 2026-10-13 | |
| A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25) T25-Fast, Mycapssa, T25-Fed - Acromegaly | Phase 1 | Completed | Triastek (Shanghai) Limited | 18 | 2026-06-25 | 2026-09-16 |
| Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA) HOP bundle - Pancreas Head Cancer, Pancreas Adenocarcinoma | Phase 4 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 400 | 2025-09-01 | 2025-12-22 |
| Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas Sacituzumab Govitecan, EKG, Brain MRI - Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2025-06-09 | 2026-01-21 |
| Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial) Octreotide (drug), Splenic Artery Ligation (SAL) - Small-for-Size Syndrome | Phase 4 | Not yet recruiting | King Faisal Specialist Hospital & Research Center | 80 | 2025-06-01 | 2025-05-15 |
| Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome terlipressin, Octreotide (drug) - Hepatorenal Syndrome | Not applicable | Completed | Lahore General Hospital | 60 | 2025-05-01 | 2026-03-10 |
| 177Lu-DOTATATE for Recurrent Meningioma Local standard of Care, 177Lu-DOTATATE - Recurrent Meningioma | Phase 2 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 136 | 2025-03-10 | 2026-06-15 |
| Graded Insulin Suppression Test P&F Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min - Insulin Resistance, Hyperinsulinemia | Phase 1 | Completed | Columbia University | 20 | 2024-09-16 | 2026-10-16 |
| Dexamethasone/Pancreatic Clamp P&F Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Prediabetic State | Phase 1 | Withdrawn | Columbia University | 2024-07-01 | 2024-07-10 | |
| Outcome of ADPKD With Octreotide LAR Octreotide - Autosomal Dominant Polycystic Kidney | Active not recruiting | Mario Negri Institute for Pharmacological Research | 70 | 2024-02-12 | 2025-09-05 | |
| Pancreatic Clamp in NAFLD Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Prediabetic State | Phase 1 | Completed | Columbia University | 18 | 2023-08-29 | 2026-01-12 |
| Role of Octreotide in Non Variceal Bleeding PPI group, PPI plus octreotide - Non-variceal Gastrointestinal Bleeding | Phase 2 / Phase 3 | Unknown | National Hepatology & Tropical Medicine Research Institute | 56 | 2023-08-23 | 2023-10-02 |
| Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements. Octreotide, Placebo - Hepatic Carcinoma, Hepatic Metastasis | Phase 2 | Unknown | Clinica Universidad de Navarra, Universidad de Navarra | 62 | 2023-08-14 | 2023-10-17 |
| Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients Somatostatin analog - Gastroenteropancreatic Neuroendocrine Tumor | Phase 4 | Recruiting | University Hospital, Antwerp | 270 | 2023-06-28 | 2024-06-14 |
| A Single-dose Study of Octreotide Injection in Healthy Adult Subjects SYHX2008 injection, Octreotide Acetate Microspheres for Injection injection, Sandostatin ® injection - Acromegaly | Phase 1 | Completed | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 56 | 2023-03-02 | 2023-10-10 |
| A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs Lutetium[177Lu] Oxodotreotide Injection, Octreotide LAR - Neuroendocrine Tumors | Phase 3 | Active not recruiting | Sinotau Pharmaceutical Group | 196 | 2022-08-31 | 2025-09-05 |
| Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled Study Octreotide - Esophageal Varices | Phase 4 | Unknown | Tanta University | 184 | 2022-06-01 | 2022-05-18 |
| A Feasibility Study of Octreotide Infusion During Liver Transplant. Octreotide Acetate, Placebo - Liver Transplantation, Renal Failure | Phase 2 | Unknown | University College, London | 30 | 2022-05-27 | 2023-05-03 |
| A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Debio 4126, Sandostatin LAR, Somatuline ATG - Acromegaly, GEP-NET | Phase 1 | Terminated | Debiopharm International SA | 19 | 2022-05-18 | 2025-11-17 |
Showing 20 of 164. Sign in to see all of them.
Acromegaly (29) · Neuroendocrine Tumors (12) · Obesity (10) · Diarrhea (9) · Neoplasms (8) · Carcinoid Tumor (7) · Insulin Resistance (7) · Carcinoma, Hepatocellular (6) · Colorectal Neoplasms (6) · Fibrosis (6) · Hepatorenal Syndrome (6) · Breast Neoplasms (5) · Diabetes Mellitus (5) · Diabetic Retinopathy (5) · Weight Loss (5)
Novartis Pharmaceuticals (17) · Novartis (7) · Aspireo Pharmaceuticals Limited (4) · Columbia University (4) · Eastern Cooperative Oncology Group (4) · Endo USA Inc., a Keenova Therapeutics Company (4) · National Cancer Institute (NCI) (4) · Alliance for Clinical Trials in Oncology (3) · Chiasma, Inc. (3) · National Hepatology & Tropical Medicine Research Institute (3) · St. James's Hospital, Ireland (3) · University of Aarhus (3) · Advanced Accelerator Applications (2) · Duke University (2) · Italfarmaco (2)
United States (74) · Italy (18) · France (17) · Germany (16) · Spain (16) · United Kingdom (15) · Canada (12) · China (12) · Netherlands (12) · Poland (11) · Hungary (8) · Sweden (8) · Belgium (7) · South Korea (7) · Czechia (6)
Joshua R Cook, MD, PhD (3) · John V Reynolds, MCh, FRCS (2) · Mary Mulcahy, MD (2) · Shiyao Chen, Professor (2) · Shlomo Melmed, MD (2) · Abhijith Hegde, MD (1) · Alex Rosin, MD (1) · Aminah Jatoi, MD (1) · Amy Case, MD (1) · Andrea M Haqq, MD (1) · Annamaria Colao, MD (1) · Ayman El Nakeeb, MD (1)
PMID 34173129, PMID 10662747, PMID 10761474, PMID 10973392, PMID 11904109, PMID 11927799, PMID 12119802, PMID 12641619, PMID 12832331, PMID 14722038, PMID 15066944, PMID 15710782, PMID 15738343, PMID 15743361, PMID 15743362, PMID 15911704, PMID 16449332, PMID 16537687, PMID 16883006, PMID 17311860, PMID 17465997, PMID 17515447, PMID 17515448, PMID 17984237, PMID 18492760, PMID 18593770, PMID 18768432, PMID 19687359, PMID 20339140, PMID 20410233, PMID 20421818, PMID 20837887, PMID 20884247, PMID 21212103, PMID 21521254, PMID 22119496, PMID 22311903, PMID 22379151, PMID 22773240, PMID 23187897, PMID 23494109, PMID 23557411, PMID 23842691, PMID 23963030, PMID 23969184, PMID 24002370, PMID 24092547, PMID 24183344, PMID 24227635, PMID 24451146
P30DK063608 (3), 2005 (2), 2019 (2), 2004 (1), 2014 (1), 2015 (1), 2016 (1), 2023 (1), K12DK133995 (1), P30CA016672 (1), T32DK007646 (1), U01CA062461 (1), U10CA023318 (1), U10CA031946 (1), U10CA032102 (1)